VolitionRx Limited (VNRX)
NYSEAMERICAN: VNRX · Real-Time Price · USD
0.628
-0.014 (-2.17%)
Jan 17, 2025, 4:00 PM EST - Market closed
VolitionRx Revenue
VolitionRx had revenue of $474.52K in the quarter ending September 30, 2024, with 187.22% growth. This brings the company's revenue in the last twelve months to $1.29M, up 97.50% year-over-year. In the year 2023, VolitionRx had annual revenue of $775.30K with 153.04% growth.
Revenue (ttm)
$1.29M
Revenue Growth
+97.50%
P/S Ratio
40.54
Revenue / Employee
$11,689
Employees
110
Market Cap
58.20M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 775.30K | 468.91K | 153.04% |
Dec 31, 2022 | 306.39K | 216.36K | 240.30% |
Dec 31, 2021 | 90.04K | 76.60K | 570.25% |
Dec 31, 2020 | 13.43K | -3.66K | -21.43% |
Dec 31, 2019 | 17.10K | - | - |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
VNRX News
- 12 days ago - Volition Issues Business Review 2024 - PRNewsWire
- 5 weeks ago - VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants - PRNewsWire
- 5 weeks ago - Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening - PRNewsWire
- 6 weeks ago - VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering - PRNewsWire
- 2 months ago - VolitionRx Limited (VNRX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update - PRNewsWire
- 2 months ago - VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update - PRNewsWire
- 2 months ago - Volition Appoints Timothy I. Still as Chairman - PRNewsWire